StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) company profile

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$135.95−1.06 (-0.77%)

Close on Nov 17, 2026Market cap $7.12BP/E –Yield –

About Axsome Therapeutics

Pharmaceutical Preparations, SIC 2834

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel therapies for central nervous system conditions. The company’s commercial offerings include AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness related to obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment. Axsome also advances an investigational pipeline addressing psychiatric and neurological indications, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, solriamfetol for conditions such as attention deficit hyperactivity disorder, and late-stage candidates for narcolepsy and fibromyalgia. Its products primarily serve adult patients diagnosed with these targeted medical conditions.

The company retains commercial rights within the United States and engages in licensing partnerships to market products internationally. Its commercial reach outside the U.S. includes distribution in Europe and selected territories across the Middle East and North Africa through a partner agreement. Axsome Therapeutics maintains its principal executive offices at One World Trade Center in New York, New York.

Summary of the business section of Axsome Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Axsome Therapeutics, Inc.
Founded
2012
Headquarters
New York, NY
Address
One World Trade Center, 29th Floor 10007
Phone
(212) 332-3241
Website
axsome.com
Employees
500, Dec 31, 2017
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Morristown, New Jersey

Stock & identifiers

Ticker
AXSM
Exchange
Nasdaq
IPO date
Nov 19, 2015
Shares outstanding
52M, Aug 3, 2026
Public float
$4.40B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1579428
CUSIP
05464T104
ISIN
US05464T1043
FIGI
BBG00B6G7GL7
Share class FIGI
BBG00B6G7GM6
LEI
549300EXGR0XLRJEIB95
EIN
45-4241907

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Herriot TabuteauChief Executive Officer, Director7,356,389
Mark L. JacobsonChief Operating Officer10,000
Nick PizzieChief Financial Officer43,355
Ari MaizelChief Commercial Officer7,500
Hunter R. MurdockGeneral Counsel6,014
Roger JeffsDirector105,279
Mark ColemanDirector434,245
Susan MahonyDirector829
Mark E. SaadDirector11,731

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.28M$33.80M$3.59M$224$125
FY2024$10.36M$10.06M$3.61M$104$93
FY2023$9.90M$9.64M$3.55M$98$94
FY2022$8.32M$28.01M$3.20M$95$90
FY2021$8.05M-$11.12M$4.51M$46$100
FY2020$7.30M$1.83M$2.40M$79$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Herriot Tabuteau
Chief Executive Officer, President and Chairman of the Board
$835.00K$5.53M$2.83M$876.75K$204.95K$10.28M-1%
Nick Pizzie
Chief Financial Officer
$530.00K$1.82M$933.33K$358.00K$86.59K$3.73M-1%
Mark Jacobson
Chief Operating Officer
$575.00K$2.08M$1.07M$388.00K$95.57K$4.21M-1%
Hunter Murdock
General Counsel
$530.00K$1.50M$766.59K$358.00K$72.64K$3.22M-1%
Ari Maizel
Chief Commercial Officer
$530.00K$1.50M$766.59K$358.00K$36.99K$3.19M-0%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 19, 2015
Offer price
$9.00
Securities offered
5,666,667
Gross proceeds
$51.00M
Exchange
Nasdaq
First trading day
Nov 19, 2015
First-day close
$8.74-2.9%
Lock-up ends (est.)
May 17, 2016

“The initial public offering price is $9.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?